Human CD20 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Immobilized Human CD20, His Tag at 2 μg/mL (100 μL/well) on the plate. Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 0.33 μg/mL determined by ELISA.
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
